Atopy: A patient-specific risk factor for diffuse lamellar keratitis

Ophthalmology

Volumn 110, Issue 1, 2003, Pages 131-137

  Boorstein, Stephen M ^a,b   Henk, Henry J ^c,d   Elner, Victor M ^e,f  

^a Davis Duehr Dean ^*  (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d Dean Foundation   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; FLAREX; FLUOROMETHALONE ACETATE; FLUOROMETHOLONE; HISTAMINE H1 RECEPTOR ANTAGONIST; OFLOXACIN; PREDNISOLONE ACETATE; REFRESH TEARS; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; ASTIGMATISM; ATOPY; DIFFUSE LAMELLAR KERATITIS; FEMALE; HUMAN; KERATITIS; KERATOMILEUSIS; MAJOR CLINICAL STUDY; MALE; MYOPIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; VISUAL IMPAIRMENT;

ADULT; ASTIGMATISM; CORNEA; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; KERATITIS; KERATOMILEUSIS, LASER IN SITU; MALE; MIDDLE AGED; MYOPIA; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037229016     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01287-3     Document Type: Article

References (49)

1. Smith RJ, Maloney RK. Diffuse lamellar keratitis. A new syndrome in lamellar refractive surgery. Ophthalmology 1998;105:1721-6.
2. Hirst LW, Vandeleur KW Jr. Laser in situ keratomileusis interface deposits. J Refract Surg 1998;14:653-4.
3. Kaufman SC, Maitchouk DY, Chiou AGY, Beuerman RW. Interface inflammation after laser in situ keratomileusis, Sands of the Sahara syndrome. J Cataract Refract Surg 1998;24:1589-93.
4. Holland SP. Update in corneal and external disease: solving the mystery of the "sands of the Sahara" syndrome (diffuse lamellar keratitis). Can J Ophthalmol 1999;34:193-4.
5. Lachance A, Tremblay M. The sands of the Sahara. Can J Ophthalmol 1998;33:387-8.
6. Lipner M. Sleuthing the sands of the Sahara. Eyeworld 1998; 3(7):4.
7. Holland SP, Mathias RG, Morck DW, et al. Diffuse lamellar keratitis related to endotoxins released from sterilizer reservoir biofilms. Ophthalmology 2000;107:1227-33; discussion 1233-4.
8. Linebarger EJ, Hardten DR, Lindstrom RL. Sands of the Sahara. In: Buratto L, Brint S, eds. LASIK: Surgical Techniques and Complications. Thorofare, NJ: Slack, Inc, 1999; chap. 36.
9. Holford-Strevens V, Warren P, Wong C, Manfreda J. Serum total immunoglobulin E levels in Canadian adults. J Allergy Clin Immunol 1984;73:516-22.
10. Cline MG, Burrows B. Distribution of allergy in a population sample residing in Tucson, Arizona. Thorax 1989;44;425-31.
11. Lynch NR, Hagel IA, Palenque ME, et al. Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. J Allergy Clin Immunol 1998;101:217-21.
12. Chatila TA. Genetics of atopic disease. Curr Opin Pediatr 1998;10:584-7.
13. Bos JD, Wierenga EA, Sillevis Smitt JH, et al. Immune dysregulation in atopic eczema. Arch Dermatol 1992;128:1509-12.
14. Businco L, Cantani A, Fiore L, et al. Current concepts on the relationship between immunodeficiency and allergy. Allergol Immunopathol (Madr) 1984;12:497-507.
15. Furukawa CT, Altman LC. Defective monocyte and polymorphonuclear leukocyte chemotaxis in atopic disease. J Allergy Clin Immunol 1978;61:288-93.
16. Wuthrich B. What is atopy? Condition, disease or a syndrome? Curr Probl Dermatol 1999;28:1-8.
17. McGill JI, Holgate ST, Church MK, et al. Allergic eye disease mechanisms. Br J Ophthalmol 1998;82:1203-14.
18. Schultz CL, Morck DW, McKay SG, et al. Lipopolysaccharide induced acute red eye and corneal ulcers. Exp Eye Res 1997;64:3-9.
19. Kennedy M, Kim KH, Harten B, et al. Ultraviolet irradiation induces the production of multiple cytokines by human corneal cells. Invest Ophthalmol Vis Sci 1997;38:2483-91.
20. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res 1999;18:293-309.
21. Wilson SE, He YG, Weng J, et al. Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue organization and wound healing, Exp Eye Res 1996;62:325-7.
22. Planck SR, Rich LF, Ansel JC, et al. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocul Immunol Inflamm 1997;5:95-100.
23. Vesaluoma MH, Tervo TT, Tenascin and cytokines in tear fluid after photorefractive keratectomy. J Refract Surg 1998; 14:447-54.
24. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000;19:113-29.
25. Elner VM, Strieter RM, Pavilack MA, et al. Human corneal interleukin-8. IL-1 and TNF-induced gene expression and secretion. Am J Pathol 1991;139:977-88.
26. Cubitt CL, Tang Q, Monteiro CA, et al. IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci 1993;34:3199-206.
27. Sobottka Ventura AC, Engelmann K, Dahinden C, Bohnke M. Endotoxins modulate the autocrine function of organ cultured donor corneas and increase the incidence of endothelial cell death. Br J Ophthalmol 1997;81:1093-8.
28. Song PI, Abraham TA, Park Y, et al. The expression of functional LPS receptor proteins CD 14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci 2001;42:2867-77.
29. Elner VM, Elner SG, Pavilack MA, et al. Intercellular adhesion molecule-1 in human corneal endothelium. Modulation and function. Am J Pathol 1991;138:525-36.
30. Yamaguchi K, Takahashi Y, Takahashi S, et al. Distribution of intercellular adhesion molecule-1 on leukocytes and corneal endothelium after endotoxin stimulation in rats, Int Ophthalmol 1995;19:303-6.
31. Colditz I, Zwahlen R, Dewald B, Baggiolini M. In vivo inflammatory activity of neutrophil-activity factor, a novel chemotactic peptide derived from human monocytes. Am J Pathol 1989;134:755-60.
32. Maio M, Tessitori G, Pinto A, et al. Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol 1989;143:181-8.
33. Davies RJ, Bagnall AC, McCabe MA, et al. Antihistamines: topical vs oral administration. Clin Exp Allergy 1996; 26(Suppl 3):11-7.
34. Hingorani M, Calder VL, Buckley RJ, Lightman SL. The role of conjunctival epithelial cells in chronic ocular allergic disease. Exp Eye Res 1998;67:491-500.
35. Schultz CL, Buret AG, Olson ME, et al. Lipopolysaccharide entry in the damaged cornea and specific uptake by polymorphonuclear neutrophils. Infect Immun 2000;68:1731-4.
36. Ciprandi G, Passalacqua G, Canonica GW. Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 1999;29(Suppl 3):49-53.
37. Ciprandi G, Buscaglia S, Catrullo A, et al. Antiallergic activity of azelastine eye drops. Clin Exp Allergy 1996;26:187-92.
38. Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997;73:145-53.
39. Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997;27:1175-83.
40. Weimer LK, Gamache DA, Yanni JM. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: inhibition by the histamine H1 antagonist emedastine. Int Arch Allergy Immunol 1998;155:288-93.
41. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643-7.
42. Ciprandi G, Catrullo A, Cerqueti P, et al. Loratadine reduces the expression of ICAM-1. Allergy 1998;53:545-6.
43. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95:612-21.
44. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997;52:33-40.
45. Bascom R, Pipkorn U, Lichtenstein LM, et al. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pre-treatment. Am Rev Respir Dis 1988;138:406-12.
46. Canonica GW, Ciprandi G, Passalacqua G, et al. Molecular events in allergic inflammation: experimental models and possible modulation. Allergy 1997;52:25-30.
47. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effects of deflazacort on allergen-specific conjunctival challenge. Eur J Clin Pharmacol 1993;45(Suppl 1):S35-41.
48. Burnstine MA, Elner SG, Elner VM. Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A. Br J Ophthalmol 1998;82:318-22.
49. Maloney RK, Binder PS, Machat JJ, et al. Sterile interface inflammation after laser in situ keratomileusis: experience and opinions. J Refract Surg 1988;14:661-6.